Prosecution Insights
Prosecution Insights
20 pending office actions • 15 art units • 17 examiners • 0 of 20 (0%) have an AI response strategy ready • 13 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 20 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 20 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (5%) |
| §103 only | 14 (70%) |
| §102 only | 1 (5%) |
| §112 only | 1 (5%) |
| No statute on record | 3 (15%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HANEY, AMANDA MARIE | 4 | 36.6% | +44.1% |
| LANNU, JOSHUA DARYL DEANON | 1 | 82.5% | +23.7% |
| LE, LINH GIANG | 1 | 65.9% | -4.7% |
| LAMPRECHT, JOEL | 1 | 81.4% | +16.4% |
| BELL, SARA ELIZABETH | 1 | 73.5% | +39.9% |
| FETTEROLF, BRANDON J | 1 | 49.5% | +14.6% |
| REYNOLDS, FRED H | 1 | 33.0% | +39.2% |
| VANN-OJUEKAIYE, KENDRA RAYCHELL | 1 | 0.0% | +0.0% |
| RIVERS, LINDSEY RAE | 1 | 62.7% | +62.2% |
| SMITH, PETER DANIEL | 1 | 49.2% | +50.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19288971 | MONITORING ORGAN MORPHOLOGY FOR RADIATION TREATMENT DELIVERY USING ULTRASOUND | LANNU, JOSHUA DARYL DEANON | 12d |
| 18578948 | Augmented Reality-Driven Guidance for Interventional Procedures | LAMPRECHT, JOEL | 12d |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17127237 | Cardiomyocyte-Specific Biological Markers and Uses Thereof | BALLARD, KIMBERLY | 146d overdue |
| 18041534 | Gene Expression Signature for Predicting Immunotherapy Response and Methods of Use | VANN-OJUEKAIYE, KENDRA RAYCHELL | 41d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17493230 | ASSESSING CONDITIONS IN TRANSPLANT SUBJECTS USING DONOR-SPECIFIC CELL-FREE DNA | HANEY, AMANDA MARIE | 141d overdue |
| 18040459 | Embolic Protection System | RIVERS, LINDSEY RAE | 53d overdue |
| 18057494 | COMPOSITIONS AND METHODS FOR REDUCING CELL-FREE DNA | SMITH, PETER DANIEL | 28d overdue |
| 18404829 | METHODS FOR ASSESSING RISK USING TOTAL AND SPECIFIC CELL-FREE DNA | HANEY, AMANDA MARIE | 16d overdue |
| 16623719 | ASSESSING CONDITIONS IN TRANSPLANT SUBJECTS USING DONOR-SPECIFIC CELL-FREE DNA | HANEY, AMANDA MARIE | 2d overdue |
| 19288971 | MONITORING ORGAN MORPHOLOGY FOR RADIATION TREATMENT DELIVERY USING ULTRASOUND | LANNU, JOSHUA DARYL DEANON | 12d |
| 18578948 | Augmented Reality-Driven Guidance for Interventional Procedures | LAMPRECHT, JOEL | 12d |
| 18252073 | Peptide Inhibitors of Human Mitochondrial Fission Protein 1 and Methods of Use | REYNOLDS, FRED H | 14d |
| Art Unit | Apps |
|---|---|
| 1682 | 5 |
| 3791 | 2 |
| 3686 | 1 |
| 3798 | 1 |
| 1625 | 1 |
| 1626 | 1 |
| 1658 | 1 |
| 3771 | 1 |
| 3781 | 1 |
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19288971 | MONITORING ORGAN MORPHOLOGY FOR RADIATION TREATMENT DELIVERY USING ULTRASOUND | LANNU, JOSHUA DARYL DEANON | 3791 | §103 | Final Rejection | 12d | Pending | Aug 01, 2025 |
| 18984890 | SYSTEMS AND METHODS FOR ESTIMATING HISTOLOGICAL FEATURES FROM MEDICAL IMAGES USING A TRAINED MODEL | LE, LINH GIANG | 3686 | §103 | Non-Final OA | 72d overdue | Pending | Dec 17, 2024 |
| 18578948 | Augmented Reality-Driven Guidance for Interventional Procedures | LAMPRECHT, JOEL | 3798 | §103 | Non-Final OA | 12d | Pending | Jan 12, 2024 |
| 18404829 | METHODS FOR ASSESSING RISK USING TOTAL AND SPECIFIC CELL-FREE DNA | HANEY, AMANDA MARIE | 1682 | Other | Final Rejection | 16d overdue | Pending | Jan 04, 2024 |
| 18287632 | Quinazoline Derivatives, Pharmaceutical Compositions, and Therapeutic Uses Related to Nox Inhibition | BELL, SARA ELIZABETH | 1625 | §112 | Non-Final OA | 79d | Pending | Oct 19, 2023 |
| 18546633 | Treatment of Hypertension-Related and Vascular Diseases | FETTEROLF, BRANDON J | 1626 | §103 | Final Rejection | 70d | Pending | Aug 16, 2023 |
| 18252073 | Peptide Inhibitors of Human Mitochondrial Fission Protein 1 and Methods of Use | REYNOLDS, FRED H | 1658 | §102 | Non-Final OA | 14d | Pending | May 08, 2023 |
| 18041534 | Gene Expression Signature for Predicting Immunotherapy Response and Methods of Use | VANN-OJUEKAIYE, KENDRA RAYCHELL | 1682 | §103 | Final Rejection | 41d | Pending | Feb 13, 2023 |
| 18040459 | Embolic Protection System | RIVERS, LINDSEY RAE | 3771 | §103 | Final Rejection | 53d overdue | Pending | Feb 03, 2023 |
| 18057494 | COMPOSITIONS AND METHODS FOR REDUCING CELL-FREE DNA | SMITH, PETER DANIEL | 3781 | §103 | Final Rejection | 28d overdue | Pending | Nov 21, 2022 |
| 17911022 | 3-(2-(Aminoethyl)-Indol-4-ol Derivatives, Methods of Preparation Thereof, and the Use as 5-HT2 Receptor Modulators | BURKETT, DANIEL JOHN | 1624 | §103 | Non-Final OA | 46d overdue | Pending | Sep 12, 2022 |
| 17690672 | Blood Infusion System for Controlling Concentration of Calcium in Blood Infusate | WITTLIFF, KATERINA ANNA | 3783 | §103 | Final Rejection | 72d overdue | Pending | Mar 09, 2022 |
| 17493230 | ASSESSING CONDITIONS IN TRANSPLANT SUBJECTS USING DONOR-SPECIFIC CELL-FREE DNA | HANEY, AMANDA MARIE | 1682 | Other | Non-Final OA | 141d overdue | Pending | Oct 04, 2021 |
| 17493186 | METHODS FOR ASSESSING RISK USING TOTAL CELL-FREE DNA | ALLEN, SARAH ELIZABETH | 1637 | §103 | Final Rejection | 12d | Pending | Oct 04, 2021 |
| 17442968 | Tip60 Inhibitors and Methods of Use for Cardiovascular Disease | BARSKY, JARED | 1628 | §103 | Non-Final OA | 15d | Pending | Sep 24, 2021 |
| 17473559 | Atrioventricular Valve Repair Ring | WOZNICKI, JACQUELINE | 3774 | §103 | Final Rejection | 50d overdue | Pending | Sep 13, 2021 |
| 17427005 | Systems and Methods for Sound Mapping of Anatomical and Physiological Acoustic Sources Using an Array of Acoustic Sensors | PORTILLO, JAIRO H | 3791 | §103 | Final Rejection | 88d overdue | Pending | Jul 29, 2021 |
| 17127237 | Cardiomyocyte-Specific Biological Markers and Uses Thereof | BALLARD, KIMBERLY | 1675 | §101 | Non-Final OA | 146d overdue | Pending | Dec 18, 2020 |
| 16623725 | TRANSPLANT PATIENT MONITORING WITH CELL-FREE DNA | HANEY, AMANDA MARIE | 1682 | §103 | Non-Final OA | 27d | Pending | Dec 17, 2019 |
| 16623719 | ASSESSING CONDITIONS IN TRANSPLANT SUBJECTS USING DONOR-SPECIFIC CELL-FREE DNA | HANEY, AMANDA MARIE | 1682 | Other | Final Rejection | 2d overdue | Pending | Dec 17, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial